• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content


Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

AstraZeneca Business Objects Case Study






Total Views
Views on SlideShare
Embed Views



3 Embeds 64

http://www.softwaresherpa.com 62
http://webcache.googleusercontent.com 1
http://www.slideee.com 1



Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    AstraZeneca Business Objects Case Study AstraZeneca Business Objects Case Study Document Transcript

    • United Kingdom AstraZeneca 98 B I S TA NDA R D IZ AT I O N CHALLENGE 1 To improve visibility and access of global R&D project management information SOLUTION 1 BusinessObjects provides information to over “In this highly competitive business sector, time-to-market dictates brand leadership 5,000 R&D users globally and revenue generation. Business Objects business intelligence solution has enabled AstraZeneca to improve project management, cost control, and resource utilization, 1 BusinessObjects Dashboard and is helping us achieve competitive research and development timescales.” Manager will David Scanlon, Business Manager, AstraZeneca deliver key performance indicators to senior management Critical Need to Reduce “To support our requirement to accelerate drug development, AstraZeneca requires fast and easy BENEFITS Time-to-Market access to global R&D information,” says Chris 1 Global AstraZeneca has over 12,000 research and Saxby, IT Consultant, AstraZeneca. transparency of development (R&D) employees across six R&D information international sites and spends over $3 billion Improved Visibility to R&D Data 1 Improved resource annually on R&D, the equivalent of over $10 utilization To provide complete visibility of R&D million every working day. 1 Tighter cost control information across the world, AstraZeneca 1 Accelerating drug Drug development is highly competitive, and has developed and deployed the Matrix each day they saved getting a new brand to project management system. This system uses market saves millions of dollars. Drug patents BusinessObjects to query and analyze global last 20-25 years, and it typically takes 8-12 R&D information stored centrally in an Oracle years to bring a drug to market. Therefore, the data warehouse. shorter the product development and clinical Over 5,000 users across AstraZeneca's six trial, the longer a company has to establish international R&D sites can access and brand leadership and generate revenues interrogate information on project schedules, before a competitor can bring generic project costs, and resource utilization. products to market. In addition, the company has selected Reduced time-to-market is dependent upon BusinessObjects as its standard business maximizing project management efficiency, intelligence solution, and it is used across resource utilization, and cost control. other core areas of the business such as Immediate access to one consistent view of manufacturing, finance, and marketing. R&D information is critical to support these processes.
    • P H A R M AC E U T I CA L / H E A LT H CA R E 99 “ Immediate access to R&D information is a critical component in the race to be first-to-market in the pharmaceutical industry. With BusinessObjects, we now have a platform to deliver this information globally in a flexible manner that supports constant innovation and change. As a result, we aim to speed development, better manage costs, and ultimately reduce time-to- market. Productivity is the key industry challenge. ” The pharmaceutical giant is also implementing This fast and easy access to R&D data provides a BusinessObjects Dashboard Manager in conjunction greater global view of project activity and of how with Advizor Solutions technology to deliver much R&D is spending on developing new dynamic at-a-glance displays that show the status products. And this R&D insight enables more of key performance indicators across R&D to senior accurate project scheduling, project budgeting, management. and resource allocation—helping AstraZeneca to plan more effectively and reduce costs. According to Saxby, “Business Objects solutions are transforming the availability and accessibility of R&D Leveraging the information provided by project information within AstraZeneca.” BusinessObjects, AstraZeneca is gaining a significant competitive edge by accelerating its BI Enables Competitive Edge time-to-market for new products. A faster development process helps AstraZeneca to launch BI solutions from Business Objects enable products earlier in order to secure early brand AstraZeneca to track, understand, and manage the leadership and increased revenues. huge volumes of project data that it creates every day. Senior management, development teams, and therapeutic area teams all have instant access to one consolidated view of up-to-date R&D information to help them make faster and more confident decisions. About AstraZeneca 1 Activity: Pharmaceuticals AstraZeneca is one of the world’s leading pharmaceutical companies, engaged in the 1 Sales figures: $18.849 million research, development, manufacture, and marketing of prescription pharmaceuticals and 1 Staff: the supply of healthcare services. AstraZeneca has sales activities in over 100 countries 12,000 in R&D and manufacturing facilities in 19 countries. 1 Date founded: 1999